GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.

Guizhou Bailing Group Pharmaceutical Co., Ltd.

002424

CNE100000PY3

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
3.22 ^CNY	+2.22%		+2.88%	-60.30%

Jul. 02	Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	CI
May. 21	Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from FTSE All-World Index	CI

Zhang Shanlin completed the acquisition of 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Yong for approximately ¥500 million.

December 20, 2022

Zhang Shanlin agreed to acquire 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) from Jiang Yong for approximately ¥500 million on December 7, 2022.

Zhang Shanlin completed the acquisition of 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. (SZSE:002424) from Jiang Yong for approximately ¥500 million on December 19, 2022.

Latest news about Guizhou Bailing Group Pharmaceutical Co., Ltd.

Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	Jul. 02	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from FTSE All-World Index	May. 20	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.(XSEC:002424) dropped from S&P Global BMI Index	May. 09	CI
Large-Scale Equipment Renewals Seen to Raise Demand for Chinese High-End Steel Products, Trade Body Says	May. 03	MT
China to Tweak Production Limits for Steel as Industry Faces Low Prices, Oversupply	May. 02	MT
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 29	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on February 3, 2024.	Apr. 02	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	Feb. 02	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	Feb. 01	CI
Bailing Group Pharma Gets Green Light for Clinical Trial of New Hepatitis B Drug	Dec. 28	MT
China steel association says EU carbon tax a new trade barrier, calls for more talks	Nov. 03	RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
China’s Steel Consumption Falls 1.5% in January-September Period	23-10-24	MT
China steel supply needs adjusting, industry official says	23-10-24	RE
EU to launch first phase of world-first CO2 border tax	23-09-13	RE
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-24	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-07-10	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback announced on January 9, 2023 has closed with 12,096,900 shares, representing 0.87% for CNY 100.01 million.	23-07-06	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-07-04	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Announces Management Appointments	23-06-06	CI
Guizhou Bailing Group Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-28	CI
Tranche Update on Guizhou Bailing Group Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on January 9, 2023.	23-04-03	CI
Zhejiang Futures Co., Ltd completed the acquisition of 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei.	23-03-30	CI
Zhejiang Futures Co., Ltd agreed to acquire a 11.17% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Wei for approximately CNY 210 million.	23-02-28	CI
GZ Bailing Buys Ownership of Traditional Chinese Drug for 20 Million Yuan; Shares Rose 3%	23-01-16	MT

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

Duration

Period

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

More charts

Company Profile

GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD. is a China-based company, principally engaged in the manufacture and distribution of Chinese patent medicines. The Company is also engaged in the provision of Chinese medicine materials. The Company is also engaged in the distribution of fertilizers and purified water, and the operation of medical institutions. The Company conducts its businesses mainly within domestic markets.

Sector

Pharmaceuticals

Calendar

2024-08-22 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
GUIZHOU BAILING GROUP PHARMACEUTICAL CO., LTD.	-60.30%	595M
DONG-E-E-JIAO CO.,LTD.	+27.19%	5.36B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-33.59%	3.4B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-2.97%	2.9B
TASLY PHARMACEUTICAL GROUP CO., LTD	-24.21%	2.53B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-10.11%	2.27B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+43.66%	1.84B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+46.15%	1.42B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+41.90%	1.38B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-13.92%	1.37B

Alternative Medicine

Guizhou Bailing Group Pharmaceutical Co., Ltd.

Equities

002424

CNE100000PY3

Pharmaceuticals

Zhang Shanlin completed the acquisition of 3.83% stake in Guizhou Bailing Group Pharmaceutical Co., Ltd. from Jiang Yong for approximately ¥500 million.

Latest news about Guizhou Bailing Group Pharmaceutical Co., Ltd.

Chart Guizhou Bailing Group Pharmaceutical Co., Ltd.

Company Profile

Income Statement Evolution

Annual profits - Rate of surprise

Sector Alternative Medicine